SCIENTIFIC EVIDENCE

The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation.

Cellular & molecular immunology

Luo F, Li H, Ma W, Cao J, Chen Q, Lu F, Qiu M, Zhou P, Xia Z, Zeng K, Zhan J, Zhou T, Luo Q, Pan W, Zhang L, Lin C, Huang Y, Zhang L, Yang D, Zhao H.

Publication Overview

Key findings, Countstar context, and access to the original paper.

2024

Cancer Research

Immunology

Single-Cell Analysis

No items found.

Key Finding

Using single-cell RNA sequencing, the authors found that APG-2575 polarized M2-like immunosuppressive macrophages toward the M1-like immunostimulatory phenotype with increased CCL5 and CXCL10 secretion, restoring T-cell function and promoting a favorable immunotherapy response.

Countstar Connection

Cell assessment in cell suspensions was performed with Countstar (model not specified) during preparation for single-cell or single-nucleus analysis.

Stay Connected to

Get new publications, application notes, cell analysis insights, and Countstar updates delivered to your inbox.

Meet us online